Skip to main content

Kardigan, Inc 8-K, filed Nov 12, 2026

Kardigan, Inc. (KARD)

8-K 2026-11-12 For: 2026-11-12
View Original
Added on November 12, 2026

About this 8-K

Kardigan, Inc filed this 8-K on November 12, 2026.

Kardigan completed enrollment in Cohort 2 of the Phase 2b danicamtiv KINSHIP-DCM trial, with topline data expected in 2Q 2027; it also completed ataciguat KATALYST-AV Phase 2b enrollment, with data expected in 2H 2027. Cash was $591.4 million. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 9.01: Financial statements and exhibits